vaccin
facil
commun
calcul
proport
children
random
hiv
infect
averag
weight
annual
enrol
studi
hiv
seropreval
antenat
women
commun
nation
seropreval
survey
women
attend
public
antenat
clinic
south
africa
depart
health
pretoria
south
africa
seropreval
commun
increas
weight
averag
use
vertic
transmiss
rate
commun
time
estim
gray
ge
mcintyr
ja
lyon
sf
xi
th
intern
confer
aid
vancouv
abstract
estim
preval
hiv
infect
children
commun
respiratori
viral
vaccin
includ
influenza
vaccin
provid
cours
studi
littl
likelihood
access
vaccin
children
studi
children
receiv
immun
expand
programm
immun
south
africa
provid
influenza
vaccin
parent
legal
guardian
sign
written
inform
consent
prior
enrol
children
approv
studi
obtain
committe
studi
human
studi
doctor
examin
admit
children
respons
determin
presenceabs
clinic
sign
day
admiss
studydoctor
howev
involv
manag
children
perform
blood
cultur
hospit
children
use
autom
system
bact
alert
organon
teknika
investig
children
hospit
lower
respiratori
tract
infect
lrti
ie
diagnosi
either
bronchiol
pneumonia
made
presenc
detail
methodolog
perform
nasopharyng
aspir
screen
specif
respiratori
virus
specif
rsv
influenza
ab
parainfluenza
type
piv
adenoviru
describ
perform
viral
test
septemb
nation
institut
virolog
south
africa
thereaft
respiratori
mening
pathogen
research
unit
briefli
state
perform
respiratori
viral
screen
use
indirect
immunofluoresc
assay
light
diagnost
respiratori
panel
vital
screen
identif
kit
chemicon
intern
inc
temecula
ca
usa
includ
poolscreen
investig
virus
follow
screen
influenza
influenza
b
piv
adenoviru
subtyp
piv
consist
throughout
studi
result
piv
type
includ
viru
due
piv
subtyp
screen
specimen
rsv
perform
shellvial
cultur
sampl
test
neg
rsv
posit
respiratori
viral
panel
pool
screen
specimen
process
nation
institut
virolog
perform
indirect
immunofluoresc
without
shellvial
cultur
specimen
process
respiratori
mening
pathogen
research
unit
absenc
tissu
cultur
throughout
studi
well
lack
shellvial
cultur
latter
part
studi
may
result
lower
sensit
detect
studi
virus
risk
would
howev
equal
distribut
children
two
arm
studi
furthermor
sensit
immunofluoresc
diagnos
respiratori
viral
infect
report
similar
tissuecultur
method
investig
clinician
inform
result
viral
studi
blind
vaccin
statu
child
per
protocol
pp
analysi
children
includ
pp
analysi
day
receipt
three
dose
studi
vaccin
interv
least
day
dose
studyvaccin
third
dose
studyvaccin
given
day
age
intenttotreat
itt
analysi
children
random
receiv
least
singl
dose
studi
vaccin
children
includ
itt
analysi
date
receipt
first
dose
vaccin
clinic
lrti
hospit
children
diagnosi
lrti
made
studi
doctor
criteria
use
diagnos
clinic
lrti
includ
presenc
casedefinit
sever
sever
lrti
andor
presenc
adventiti
sound
chest
auscult
andor
presenc
whoac
chest
radiographi
cxr
clinic
diagnosi
lrti
includ
children
pneumonia
bronchiol
exclud
children
diagnos
laryngotracheobronch
pneumonia
children
diagnos
pneumonia
presenc
whoac
child
fulfil
clinic
diagnosi
lrti
without
wheez
chest
auscult
rale
andor
bronchial
breath
bronchiol
children
diagnos
bronchiol
presenc
wheez
chest
auscult
perform
one
studi
doctor
absenc
document
alveolar
consolid
chest
radiograph
whoac
presenc
dens
opac
may
fluffi
consolid
portion
whole
lobe
entir
lung
often
contain
air
bronchogram
sometim
associ
pleural
effus
pleural
effus
later
pleural
space
associ
pulmonari
infiltr
effus
larg
enough
obscur
opac
perform
analys
use
stata
version
statacorp
lp
colleg
station
tx
usa
epi
info
version
center
diseas
control
atlanta
ga
usa
calcul
vaccin
efficaci
e
calcul
rel
risk
rr
first
episod
ill
epi
info
version
e
rr
use
taylor
seri
expans
calcul
confid
limit
rel
risk
compar
proport
use
pearson
chi
squar
test
fischer
exact
test
expect
cell
valu
observ
design
trial
end
followup
occurr
per
protocol
analysi
invas
diseas
case
nonhiv
popul
suffici
obtain
power
detect
vaccin
efficaci
determin
simultan
endpoint
approxim
case
whoac
pneumonia
case
would
obtain
nonhivv
popul
provid
power
detect
vaccin
efficaci
thu
design
trial
sampl
size
larg
enough
detect
quit
low
whoac
pneumonia
power
avail
confid
make
observ
found
vaccin
efficaci
total
clinic
pneumonia
pneumonia
identifi
viru
fulli
immun
hiv
uninfect
children
respect
lack
signific
differ
point
estim
confid
interv
vaccin
efficaci
individu
viral
associ
pneumonia
suggest
vaccin
similar
activ
viral
associ
pneumonia
analyz
data
hospit
occur
novemb
date
close
databas
analysi
primari
object
studi
analyz
vaccin
efficaci
calcul
first
episod
pneumonia
bronchiol
independ
ie
child
would
includ
st
episod
either
event
elig
similarli
vaccin
efficaci
calcul
st
episod
individu
respiratori
viral
associ
ill
analyz
independ
virus
viz
child
consid
independ
individu
analys
censor
inclus
includ
altern
analysi
child
includ
twice
analysi
multipl
episod
endpoint
occur
includ
first
episod
analysi
